Targeted Ruthenium-Based Anti-Inflammatory Nanoagent for Enhanced Rheumatoid Arthritis Treatment

Abstract

The inhibition of joint synovial inflammation, caused by poor oxygen (O₂) supply and excessive reactive oxygen species (ROS) generation, is an important treatment strategy for rheumatoid arthritis (RA). Herein, we formulated a targeted ruthenium-based anti-inflammatory nanosystem consisting of ruthenium clusters-loaded F127-organosilica micelles with folic acid (FA) modification (RuFOMs-FA) for RA treatment through a two-stage macrophage regulatory mechanism. At the first stage, RuFOMs-FA exhibited excellent photothermal capability with a high photothermal conversion efficiency of 55.3% upon external-field 808 nm NIR irradiation, which further induced the death of M1 macrophages through the folic acid-mediated active targeting pathway. Further, the resultant nanoagent mimicked enzymes displayed catalase-like and superoxide dismutase-like activities for endogenously scavenging ROS and producing O₂ to induce the polarization of pro-inflammatory M1 to anti-inflammatory M2 macrophages in the RA physiological environment. More importantly, RuFOMs-FA effectively alleviated hypoxia, inflammation, and cartilage destruction in the synovial joints in a rat RA model by the two-stage macrophage regulatory mechanism. Consequently, it is highly expected that the developed RuFOMs-FA could be applied as a new noble metal-based anti-inflammatory candidate nanosystem for efficient and safe RA treatment.

Keywords

anti-inflammatory / organosilica / photothermal / rheumatoid arthritis / ruthenium

References

[1] G. S. Firestein, “Evolving Concepts of Rheumatoid Arthritis,” Nature423 (2003): 356.

[2] I. B. McInnes and G. Schett, “Pathogenetic Insights From the Treatment of Rheumatoid Arthritis,” Lancet389 (2017): 2328.

[3] C. A. Wijbrandts and P. P. Tak, “Prediction of Response to Targeted Treatment in Rheumatoid Arthritis,” Mayo Clinic Proceedings92 (2017): 1129.

[4] J. M. Kahlenberg and D. A. Fox, “Advances in the Medical Treatment of Rheumatoid Arthritis,” Hand Clinics27 (2011): 11.

[5] J. Zhou, Z. Zhang, J. Joseph, et al., “Biomaterials and Nanomedicine for Bone Regeneration: Progress and Future Prospects,” Exploration2021, 1, 20210011.

[6] S. Wang, J. Lv, S. Meng, J. Tang, and L. Nie, “Recent Advances in Nanotheranostics for Treat-to-Target of Rheumatoid Arthritis,” Advanced Healthcare Materials9 (2020): e1901541.

[7] R. F. Loeser, “Molecular Mechanisms of Cartilage Destruction: Mechanics, Inflammatory Mediators, and Aging Collide,” Arthritis and Rheumatism54 (2006): 1357.

[8] J. S. Smolen, D. Aletaha, M. Koeller, M. H. Weisman, and P. Emery, “New Therapies for Treatment of Rheumatoid Arthritis,” Lancet370 (2007): 1861.

[9] B. N. Brown, B. D. Ratner, S. B. Goodman, S. Amar, and S. F. Badylak, “Macrophage Polarization: An Opportunity for Improved Outcomes in Biomaterials and Regenerative Medicine,” Biomaterials33 (2012): 3792.

[10] H. Manabe, Y. Nasu, T. Komiyama, et al., “Inhibition of Histone Deacetylase Down-Regulates the Expression of Hypoxia-Induced Vascular Endothelial Growth Factor by Rheumatoid Synovial Fibroblasts,” Inflammation Research57 (2008): 4.

[11] B. Kim, H. B. Pang, J. Kang, J. H. Park, E. Ruoslahti, and M. J. Sailor, “Immunogene Therapy With Fusogenic Nanoparticles Modulates Macrophage Response to Staphylococcus aureus,” Nature Communications9 (2018): 1969.

[12] A. Laria, A. Lurati, M. Marrazza, D. Mazzocchi, K. A. Re, and M. Scarpellini, “The Macrophages in Rheumatic Diseases,” Inflammation Research9 (2016): 1.

[13] S. Bhattacharya and A. Aggarwal, “M2 Macrophages and Their Role in Rheumatic Diseases,” Rheumatology International39 (2019): 769.

[14] U. Fearon, M. Canavan, M. Biniecka, and D. J. Veale, “Hypoxia, Mitochondrial Dysfunction and Synovial Invasiveness in Rheumatoid Arthritis,” Nature Reviews Rheumatology12 (2016): 385.

[15] C. H. Jeon, J. K. Ahn, J.-Y. Chai, et al., “Hypoxia Appears at Pre‑Arthritic Stage and Shows Co‑Localization With Early Synovial Inflammation in Collagen Induced Arthritis,” Clinical and Experimental Rheumatology26 (2008): 646.

[16] C. L. Peters, C. J. Morris, P. I. Mapp, D. R. Blake, C. E. Lewis, and V. R. Winrow, “The Transcription Factors Hypoxia-Inducible Factor 1α and Ets-1 Colocalize in the Hypoxic Synovium of Inflamed Joints in Adjuvant-Induced Arthritis,” Arthritis and Rheumatism50 (2004): 291.

[17] T. Wang, H. Liu, G. Lian, S. Y. Zhang, X. Wang, and C. Jiang, “HIF1 α-Induced Glycolysis Metabolism is Essential to the Activation of Inflammatory Macrophages,” Mediators of Inflammation2017 (2017): 9029327.

[18] G. Lan, K. Ni, Z. Xu, S. S. Veroneau, Y. Song, and W. Lin, “Nanoscale Metal-Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy,” Journal of the American Chemical Society140 (2018): 5670.

[19] S. Srivastava, D. Singh, and M. R. Singh, “Folate-Conjugated Superoxide Dismutase Adsorbed Over Antioxidant Mimicking Nanomatrix Frameworks for Treatment of Rheumatoid Arthritis,” Journal of Pharmaceutical Sciences107 (2018): 1530.

[20] M. Chen, J. C. K. Amerigos, Z. Su, et al., “Folate Receptor-Targeting and Reactive Oxygen Species-Responsive Liposomal Formulation of Methotrexate for Treatment of Rheumatoid Arthritis,” Pharmaceutics11 (2019): 11110582.

[21] J. Huang, G. Deng, S. Wang, et al., “A NIR-II Photoactivatable “ROS Bomb” With High-Density Cu₂O-Supported MoS₂ Nanoflowers for Anticancer Therapy,” Advancement of Science10 (2023): 2302208.

[22] C. Z. S. Akdogan, B. Gokcal, M. Polat, K. O. Hamaloglu, C. Kip, and A. Tuncel, “Porous, Oxygen Vacancy Enhanced CeO_2−x Microspheres With Efficient Enzyme-Mimetic and Photothermal Properties,” ACS Sustainable Chemistry & Engineering10 (2022): 9492.

[23] L. Yang, C. Ren, M. Xu, et al., “Rod-Shape Inorganic Biomimetic Mutual-Reinforcing MnO₂-Au Nanozymes for Catalysis-Enhanced Hypoxic Tumor Therapy,” Nano Research13 (2020): 2246.

[24] Q. Huang, Z. Liu, Y. Yang, et al., “Selenium Nanodots (SENDs) as Antioxidants and Antioxidant-Prodrugs to Rescue Islet β Cells in Type 2 Diabetes Mellitus by Restoring Mitophagy and Alleviating Endoplasmic Reticulum Stress,” Advancement of Science10 (2023): 2300880.

[25] S. Wang, R. Chen, Q. Yu, et al., “Near-Infrared Plasmon-Boosted Heat/Oxygen Enrichment for Reversing Rheumatoid Arthritis With Metal/Semiconductor Composites,” ACS Applied Material Interfaces12 (2020): 45796.

[26] B. Yang, H. Yao, J. Yang, et al., “In Situ Synthesis of Natural Antioxidase Mimics for Catalytic Anti-Inflammatory Treatments: Rheumatoid Arthritis as an Example,” Journal of the American Chemical Society144 (2022): 314.

[27] Z. Liu, L. Xie, K. Qiu, et al., “An Ultrasmall RuO₂ Nanozyme Exhibiting Multienzyme-Like Activity for the Prevention of Acute Kidney Injury,” ACS Applied Material Interfaces12 (2020): 31205.

[28] R. Huang, Z. Ding, B. P. Jiang, et al., “Artificial Metalloprotein Nanoanalogues: In Situ Catalytic Production of Oxygen to Enhance Photoimmunotherapeutic Inhibition of Primary and Abscopal Tumor Growth,” Small16 (2020): 2004345.

[29] Y. Zhao, Z. Zhang, Z. Pan, and Y. Liu, “Advanced Bioactive Nanomaterials for Biomedical Applications,” Exploration1 (2021): 20210089.

[30] W. L. Wang, Z. Guo, Y. Lu, et al., “Receptor-Mediated and Tumor-Microenvironment Combination-Responsive Ru Nanoaggregates for Enhanced Cancer Phototheranostics,” ACS Applied Material Interfaces11 (2019): 17294.

[31] S. Kang, Y. G. Gil, D. H. Min, and H. Jang, “Nonrecurring Circuit Nanozymatic Enhancement of Hypoxic Pancreatic Cancer Phototherapy Using Speckled Ru-Te Hollow Nanorods,” ACS Nano2020, 14, 4383.

[32] W. Wang, Y. Zhu, X. Zhu, et al., “Biocompatible Ruthenium Single-Atom Catalyst for Cascade Enzyme-Mimicking Therapy,” ACS Applied Material Interfaces13 (2021): 45269.

[33] D. Niu, J. He, X. Qin, et al., “Superstable and Large-Scalable Organosilica-Micellar Hybrid Nanosystem via a Confined Gelation Strategy for Ultrahigh-Dosage Chemotherapy,” Nano Letters21 (2021): 9388.

[34] R. Nagayoshi, T. Nagai, K. Matsushita, et al., “Effectiveness of Anti-Folate Receptor β Antibody Conjugated With Truncated Pseudomonas Exotoxin in the Targeting of Rheumatoid Arthritis Synovial Macrophages,” Arthritis and Rheumatism52 (2005): 2666.

[35] M. J. Turk, G. J. Breur, W. R. Widmer, et al., “Folate-Targeted Imaging of Activated Macrophages in Rats With Adjuvant-Induced Arthritis,” Arthritis and Rheumatism46 (2002): 1947.

[36] W. Xia, A. R. Hilgenbrink, E. L. Matteson, M. B. Lockwood, J. X. Cheng, and P. S. Low, “A Functional Folate Receptor is Induced During Macrophage Activation and Can be Used to Target Drugs to Activated Macrophages,” Blood113 (2009): 438.

[37] Q. Huo, J. Liu, L. Q. Wang, Y. Jiang, T. N. Lambert, and E. Fang, “A New Class of Silica Cross-Linked Micellar Core-Shell Nanoparticles,” Journal of the American Chemical Society128 (2006): 6447.

[38] A. H. Musalli, P. D. Talukdar, P. Roy, P. Kumar, and T. W. Wong, “Folate-Induced Nanostructural Changes of Oligochitosan Nanoparticles and Their Fate of Cellular Internalization by Melanoma,” Carbohydrate Polymers244 (2020): 116488.

[39] M. S. Refat, T. Altalhi, and R. F. Hassan, “Synthesis, Spectroscopic, Structural and Morphological Characterizations of Magnesium(II), Calcium(II), Strontium(II) and Barium(II) Folate Complexes,” Journal of Molecular Structure1227 (2020): 129519.

[40] C. Mao, C. X. Liang, Y. Q. Mao, L. Li, X. M. Hou, and J. Shen, “Modification of Polyethylene With Pluronics F127 for Improvement of Blood Compatibility,” Colloids and Surfaces B, Biointerfaces74 (2009): 362.

[41] I. Kuan, W. Gu, J. Wu, C. Wei, K. Chen, and C. Yu, “Effects of Grafting Poly(ethylene oxide) on the Amplification Efficiency of a Poly(dimethylsiloxane)-Based Flow-Through PCR Device,” Chemical Engineering Journal143 (2008): 326.

[42] S. B. He, P. Balasubramanian, Z. W. Chen, et al., “Protein-Supported RuO 2 Nanoparticles With Improved Catalytic Activity, in Vitro Salt Resistance, and Biocompatibility: Colorimetric and Electrochemical Biosensing of Cellular H 2 O 2,” ACS Applied Material Interfaces12 (2020): 14876.

[43] W. Wang, S. Guo, I. Lee, et al., “Hydrous Ruthenium Oxide Nanoparticles Anchored to Graphene and Carbon Nanotube Hybrid Foam for Supercapacitors,” Scientific Reports4 (2014): 4452.

[44] Z. Xiao, X. Jiang, B. Li, et al., “Hydrous RuO₂ Nanoparticles as an Efficient NIR-Light Induced Photothermal Agent for Ablation of Cancer Cells In Vitro and In Vivo,” Nanoscale7 (2015): 11962.

[45] Z. Liu, K. Qiu, X. Liao, et al., “Nucleus-Targeting Ultrasmall Ruthenium( iv ) Oxide Nanoparticles for Photoacoustic Imaging and Low-Temperature Photothermal Therapy in the NIR-II Window,” Chemical Communications56 (2020): 3019.

[46] R. Roubenoff, L. M. Freeman, D. E. Smith, L. W. Abad, C. A. Dinarello, and J. J. Kehayias, “Adjuvant Arthritis as a Model of Inflammatory Cachexia,” Arthritis and Rheumatism40 (1997): 534.

[47] S. S. Glasson, B. Askew, R. Sheppard, et al., “Deletion of Active ADAMTS5 Prevents Cartilage Degradation in a Murine Model of Osteoarthritis,” Nature434 (2005): 644.

[48] D. Huang, K. Xu, X. Huang, et al., “Remotely Temporal Scheduled Macrophage Phenotypic Transition Enables Optimized Immunomodulatory Bone Regeneration,” Small2022, 18, e2203680.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.